comparemela.com

Latest Breaking News On - Prnewswire moleculin biotech inc - Page 10 : comparemela.com

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasGill shephardWalter klempLiposomal annamycinDepartment of registration medicinal productsMoleculin biotech incDrug administrationExchange commissionEthics committeeSecurities exchangePrnewswire moleculin biotech incPolish departmentMedicinal productsChief executive officerAnnual meeting

Moleculin Engages Wolfram C M Dempke, MD, PhD, MBA as its European Chief Medical Officer

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

Nordrhein westfalenUnited statesJenene thomasWalter klempWolframcm dempkeIncyte biosciencesBristol myers squibbMunich university medical oncology departmentGlobal medical affairsKyowa kirin pharmaceutical development ltdMoleculin biotech incPrnewswire moleculin biotech incExpert at novartis oncology global clinical developmentElbland clinic holdingHead of the department haematologyUniversity of halle

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incCompany investigational new drugEmory universityDrug administrationExchange commissionSecurities exchangePrnewswire moleculin biotech incInvestigational new drugTranscription modulatorRegulatoryt cellsDiffuse interstitial pontine gliomaOrphan drug designationRare pediatric disease

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.

United statesJenene thomasWalter klempMoleculin biotech incCompany investigational new drugEmory universityDrug administrationExchange commissionSecurities exchangePrnewswire moleculin biotech incInvestigational new drugTranscription modulatorRegulatoryt cellsDiffuse interstitial pontine gliomaOrphan drug designationRare pediatric disease

Moleculin Reports Full Year Financial Results and Provides Programs Update

– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine.

United statesUnited kingdomCity ofJenene thomasWalter klempMoleculin biotech incCompany investigational new drugDrug administrationRiverside ethics committeeRiverside research ethics committeeExchange commissionPrnewswire moleculin biotech incSecurities exchangeHealthcare products regulatory agencyAcute myeloid leukemiaSoft tissue sarcoma

vimarsana © 2020. All Rights Reserved.